drugset / Trial / NCT00054808
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-randomizedOpen-labelTreatment
Summary
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.
Timeline
- Start
- 2002-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gallium nitrate | Small molecule | 300 mg/m2 | Intravenous |